Cargando…
Time in range centered diabetes care
Optimal glycemic control remains challenging and elusive for many people with diabetes. With the comprehensive clinical evidence on safety and efficiency in large populations, and with broader reimbursement, the adoption of continuous glucose monitoring (CGM) is rapidly increasing. Standardized visu...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Society for Pediatric Endocrinology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783127/ https://www.ncbi.nlm.nih.gov/pubmed/33446946 http://dx.doi.org/10.1297/cpe.30.1 |
_version_ | 1783632047424667648 |
---|---|
author | Dovc, Klemen Battelino, Tadej |
author_facet | Dovc, Klemen Battelino, Tadej |
author_sort | Dovc, Klemen |
collection | PubMed |
description | Optimal glycemic control remains challenging and elusive for many people with diabetes. With the comprehensive clinical evidence on safety and efficiency in large populations, and with broader reimbursement, the adoption of continuous glucose monitoring (CGM) is rapidly increasing. Standardized visual reporting and interpretation of CGM data and clear and understandable clinical targets will help professionals and individuals with diabetes use diabetes technology more efficiently, and finally improve long-term outcomes with less everyday disease burden. For the majority of people with type 1 or type 2 diabetes, time in range (between 70 and 180 mg/dL, or 3.9 and 10 mmol/L) target of more than 70% is recommended, with each incremental increase of 5% towards this target being clinically meaningful. At the same time, the goal is to minimize glycemic excursions: a recommended target for a time below range (< 70 mg/dL or < 3.9 mmol/L) is less than 4%, and time above range (> 180 mg/dL or 10 mmol/L) less than 25%, with less stringent goals for older individuals or those at increased risk. These targets should be individualized: the personal use of CGM with the standardized data presentation provides all necessary means to accurately tailor diabetes management to the needs of each individual with diabetes. |
format | Online Article Text |
id | pubmed-7783127 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | The Japanese Society for Pediatric Endocrinology |
record_format | MEDLINE/PubMed |
spelling | pubmed-77831272021-01-13 Time in range centered diabetes care Dovc, Klemen Battelino, Tadej Clin Pediatr Endocrinol Review Optimal glycemic control remains challenging and elusive for many people with diabetes. With the comprehensive clinical evidence on safety and efficiency in large populations, and with broader reimbursement, the adoption of continuous glucose monitoring (CGM) is rapidly increasing. Standardized visual reporting and interpretation of CGM data and clear and understandable clinical targets will help professionals and individuals with diabetes use diabetes technology more efficiently, and finally improve long-term outcomes with less everyday disease burden. For the majority of people with type 1 or type 2 diabetes, time in range (between 70 and 180 mg/dL, or 3.9 and 10 mmol/L) target of more than 70% is recommended, with each incremental increase of 5% towards this target being clinically meaningful. At the same time, the goal is to minimize glycemic excursions: a recommended target for a time below range (< 70 mg/dL or < 3.9 mmol/L) is less than 4%, and time above range (> 180 mg/dL or 10 mmol/L) less than 25%, with less stringent goals for older individuals or those at increased risk. These targets should be individualized: the personal use of CGM with the standardized data presentation provides all necessary means to accurately tailor diabetes management to the needs of each individual with diabetes. The Japanese Society for Pediatric Endocrinology 2021-01-05 2021 /pmc/articles/PMC7783127/ /pubmed/33446946 http://dx.doi.org/10.1297/cpe.30.1 Text en 2021©The Japanese Society for Pediatric Endocrinology This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License. (CC-BY-NC-ND 4.0: http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Review Dovc, Klemen Battelino, Tadej Time in range centered diabetes care |
title | Time in range centered diabetes care |
title_full | Time in range centered diabetes care |
title_fullStr | Time in range centered diabetes care |
title_full_unstemmed | Time in range centered diabetes care |
title_short | Time in range centered diabetes care |
title_sort | time in range centered diabetes care |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783127/ https://www.ncbi.nlm.nih.gov/pubmed/33446946 http://dx.doi.org/10.1297/cpe.30.1 |
work_keys_str_mv | AT dovcklemen timeinrangecentereddiabetescare AT battelinotadej timeinrangecentereddiabetescare |